Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

Benzinga Newsdesk www.benzinga.com Positive 90.5%

Neg 0% Neu 0% Pos 90.5%

Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.